Related Experiment Video

Updated: Oct 12, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K

Erratum: Near-complete response to low-dose ceritinib in recurrent infantile inflammatory myofibroblastic tumour

Abhenil Mittal1, Aarushi Gupta2, Sameer Rastogi1

  • 1Department of Medical Oncology, Dr Bhim Rao Ambedkar (BRA) Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India.

Ecancermedicalscience
|November 26, 2021
PubMed

Insights

This study corrects a previous article. The correction ensures accuracy in scientific records.

Area of Science:

  • Scientific communication
  • Publication ethics

Context:

  • Ensuring the integrity of published scientific literature is crucial.
  • Accurate record-keeping is fundamental to scientific progress.

Purpose:

  • To rectify an error in a previously published article.
  • To maintain the accuracy and reliability of scientific publications.

Summary:

  • A correction has been issued for an article published in volume 15.
  • The correction pertains to information presented on page 1 of the aforementioned article.

Impact:

  • Upholds the standards of scientific accuracy.
  • Prevents the dissemination of potentially misleading information.

Keywords:
ceritinibinfantinflammatory myofibroblastic tumourlow dose

More Related Videos

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.1K
Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer11:31

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

10.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K